179 related articles for article (PubMed ID: 1759495)
1. Controlled release microparticles for vaccine development.
O'Hagan DT; Jeffery H; Roberts MJ; McGee JP; Davis SS
Vaccine; 1991 Oct; 9(10):768-71. PubMed ID: 1759495
[TBL] [Abstract][Full Text] [Related]
2. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles.
O'Hagan DT; Jeffery H; Davis SS
Vaccine; 1993; 11(9):965-9. PubMed ID: 8212845
[TBL] [Abstract][Full Text] [Related]
3. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study.
Uchida T; Goto S
Biol Pharm Bull; 1994 Sep; 17(9):1272-6. PubMed ID: 7841952
[TBL] [Abstract][Full Text] [Related]
4. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
5. Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation.
Uchida T; Goto S; Foster TP
J Pharm Pharmacol; 1995 Jul; 47(7):556-60. PubMed ID: 8568620
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable microparticles as controlled release antigen delivery systems.
O'Hagan DT; Rahman D; McGee JP; Jeffery H; Davies MC; Williams P; Davis SS; Challacombe SJ
Immunology; 1991 Jun; 73(2):239-42. PubMed ID: 2071168
[TBL] [Abstract][Full Text] [Related]
7. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
Maloy KJ; Donachie AM; O'Hagan DT; Mowat AM
Immunology; 1994 Apr; 81(4):661-7. PubMed ID: 7518802
[TBL] [Abstract][Full Text] [Related]
8. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen.
Coombes AG; Lavelle EC; Jenkins PG; Davis SS
Vaccine; 1996 Oct; 14(15):1429-38. PubMed ID: 8994318
[TBL] [Abstract][Full Text] [Related]
9. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems.
Delgado A; Lavelle EC; Hartshorne M; Davis SS
Vaccine; 1999 Jul; 17(22):2927-38. PubMed ID: 10438065
[TBL] [Abstract][Full Text] [Related]
10. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol.
Lavelle EC; Yeh MK; Coombes AG; Davis SS
Vaccine; 1999 Feb; 17(6):512-29. PubMed ID: 10075157
[TBL] [Abstract][Full Text] [Related]
11. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.
Challacombe SJ; Rahman D; Jeffery H; Davis SS; O'Hagan DT
Immunology; 1992 May; 76(1):164-8. PubMed ID: 1628895
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
13. Induction of secretory immunity with bioadhesive poly (D,L-lactide-co-glycolide) microparticles containing Streptococcus sobrinus glucosyltransferase.
Smith DJ; Trantolo DJ; King WF; Gusek EJ; Fackler PH; Gresser JD; De Souza VL; Wise DL
Oral Microbiol Immunol; 2000 Apr; 15(2):124-30. PubMed ID: 11155176
[TBL] [Abstract][Full Text] [Related]
14. Effects of solvent selection and fabrication method on the characteristics of biodegradable poly(lactide-co-glycolide) microspheres containing ovalbumin.
Cho SW; Song SH; Choi YW
Arch Pharm Res; 2000 Aug; 23(4):385-90. PubMed ID: 10976588
[TBL] [Abstract][Full Text] [Related]
15. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
16. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles.
Vordermeier HM; Coombes AG; Jenkins P; McGee JP; O'Hagan DT; Davis SS; Singh M
Vaccine; 1995 Nov; 13(16):1576-82. PubMed ID: 8578845
[TBL] [Abstract][Full Text] [Related]
17. Self-encapsulating Poly(lactic-co-glycolic acid) (PLGA) Microspheres for Intranasal Vaccine Delivery.
Bailey BA; Desai KH; Ochyl LJ; Ciotti SM; Moon JJ; Schwendeman SP
Mol Pharm; 2017 Sep; 14(9):3228-3237. PubMed ID: 28726424
[TBL] [Abstract][Full Text] [Related]
18. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres.
Igartua M; Hernández RM; Esquisabel A; Gascón AR; Calvo MB; Pedraz JL
J Control Release; 1998 Dec; 56(1-3):63-73. PubMed ID: 9801430
[TBL] [Abstract][Full Text] [Related]
20. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
Mueller M; Schlosser E; Gander B; Groettrup M
Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
